-- 貝爾金融集團（ASX：BFG）週四向澳洲證券交易所提交的文件顯示，截至4月30日的四個月內，未經審計的稅後淨利（NPAT）為1,630萬澳元，較去年同期成長197%；營收成長37%至1.096億澳元。 文件指出，強勁的市場交易和交易活動以及平台業務的持續成長是業績成長的主要驅動力。在經歷了疲軟的上半年後，隨著2025年下半年交易環境的復甦，業績顯著改善。 文件也補充道，前四個月未經審計的市場收入為7,350萬澳元，年增62%；稅後淨利為740萬澳元，年增423%；平台收入為3,320萬澳元，年增9%；稅後淨利為890萬澳元，較去年同期成長15%。 該公司股價在最近的周四交易中上漲了6%。
Related Articles
Asia
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
$SGX:CC3
Asia
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
$BOM:544632$NSE:MEESHO
Asia
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.
$SHE:000661